Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.56 |
| ▸ | AXL | P30530 | 2/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | CLK2 | P49760 | 2/20 | 0.49 |
| ▸ | CLK3 | P49761 | 2/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | TTK | P33981 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29643873 | 1.00 | NTRK1 (0.56) | NTRK1AXLPIM1CLK2CLK3 | |
| SCHEMBL1663211 | 0.80 | AXL (0.60) | AXLCLK2DYRK1ATTKHTR2A | |
| SCHEMBL8365739 | 0.79 | NTRK1 (0.51) | NTRK1PIM1CLK2CLK3DYRK1A | |
| SCHEMBL5377700 | 0.79 | MAP2K4 (0.56) | NTRK1TTKLRRK2 | |
| SCHEMBL29644099 | 0.77 | AXL (0.55) | NTRK1AXLCLK2DYRK1AHTR2A | |
| SCHEMBL22890014 | 0.77 | AXL (0.55) | NTRK1AXLCLK2DYRK1AHTR2A | |
| SCHEMBL4008208 | 0.77 | DCLK1 (0.65) | AXLPIM1CLK2DYRK1ATTK | |
| SCHEMBL31423230 | 0.77 | DCLK1 (0.65) | AXLPIM1CLK2DYRK1ATTK | |
| SCHEMBL12193658 | 0.77 | MKNK1 (0.61) | NTRK1AXLPIM1CLK2CLK3 | |
| SCHEMBL29771525 | 0.77 | IDO1 (0.61) | NTRK1PIM1CLK2CLK3DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20230077268-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. | 2023-03-09 | — | — | US | disclosed |
| US-11427558-B1 | Indazoles and azaindazoles as LRRK2 inhibitors | ESCAPE Bio, Inc. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2022-05-26 | — | — | US | disclosed |
| EP-3997081-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | Escape Bio, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-114450274-A | Indazoles and azaindazoles as LRRK2 inhibitors | 伊斯凯普生物公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021007477-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2021-01-14 | — | — | WO | disclosed |
| WO-2021007477-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2021-01-14 | — | — | WO | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11427558-B1 | Indazoles and azaindazoles as LRRK2 inhibitors | LRRK2, PARK7, GDI2 | NTRK1 1343/4885AXL 2469/4885PIM1 2247/4885 |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | NTRK1 1343/4885AXL 2469/4885PIM1 2247/4885 |
| US-20230077268-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | NTRK1 1343/4885AXL 2469/4885PIM1 2247/4885 |
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | NTRK1 1496/4885AXL 3001/4885PIM1 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.